Home › Castration-Resistant Prostatic Cancer › Maryland
Castration-Resistant Prostatic Cancer clinical trials in Maryland
3 studies for Castration-Resistant Prostatic Cancer are looking for participants at sites in Maryland.
Cities in Maryland
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- University of Maryland, Baltimore
- Johns Hopkins Hospital, Baltimore
- Johns Hopkins Medical Institutions, Baltimore
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Johns Hopkins University, Baltimore
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07164443Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
RecruitingPhase 1
Ages 18 to 100 · Men · Updated Aug 13, 2026 · NCT05519449From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.